We are on a mission to improve patient outcomes
We create novel medicines that benefit patients in need
About ResoTher Pharma
We target neutrophil driven inflamation and act as resolution therapy
ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on discovering and developing peptide-based drugs as resolution therapy for diseases where inflammation plays a key pathological role.
RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK
ResoTher Pharma announces encouraging top-line results from its Phase 2a [...]
CFO of two companies chooses sides: “Challenging to make time add up”
“A completely new and very exciting funding opportunity,” combined with [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient [...]
Latest News
RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK
ResoTher Pharma announces encouraging top-line results from its Phase 2a [...]
CFO of two companies chooses sides: “Challenging to make time add up”
“A completely new and very exciting funding opportunity,” combined with [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient [...]
